We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.75%
2 Real Estate 2.87%
3 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESRX
76
DELISTED
Express Scripts Holding Company
ESRX
$6.31M 0.24%
84,500
– –
ADAP
77
DELISTED
Adaptimmune Therapeutics
ADAP
$6.25M 0.24%
935,368
– –
WMGI
78
DELISTED
Wright Medical Group Inc
WMGI
$5.92M 0.23%
266,781
– –
PRAH
79
DELISTED
PRA Health Sciences, Inc.
PRAH
$5.91M 0.23%
64,920
-37,080
-36% -$3.08M
EPZM
80
DELISTED
Epizyme, Inc
EPZM
$5.72M 0.22%
456,000
– –
CTMX icon
81
CytomX Therapeutics
CTMX
$714M
$5.59M 0.22%
265,045
-265,047
-50% -$5.5M
FOMX
82
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.59M 0.22%
930,398
– –
HCA icon
83
HCA Healthcare
HCA
$85.7B
$5.57M 0.21%
63,432
-31,800
-33% -$2.55M
TTPH
84
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.41M 0.21%
42,966
– –
OVID icon
85
Ovid Therapeutics
OVID
$442M
$5.29M 0.2%
535,824
+373,287
+230% +$3.43M
VTR icon
86
Ventas
VTR
$44.7B
$5.28M 0.2%
87,996
-87,995
-50% -$5.56M
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
$5.13M 0.2%
75,400
– –
AVDL
88
DELISTED
Avadel Pharmaceuticals
AVDL
$5.12M 0.2%
624,288
– –
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.11M 0.2%
129,948
+67,448
+108% +$2.52M
MYOV
90
DELISTED
Myovant Sciences Ltd.
MYOV
$5.06M 0.2%
400,000
– –
LKFT
91
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$4.99M 0.19%
53,200
+34,200
+180% +$3.24M
SYK icon
92
Stryker
SYK
$133B
$4.88M 0.19%
31,500
– –
PBYI icon
93
Puma Biotechnology
PBYI
$402M
$4.78M 0.18%
48,392
-57,103
-54% -$6.39M
TSRO
94
DELISTED
TESARO, Inc.
TSRO
$4.77M 0.18%
57,595
– –
DOC
95
DELISTED
PHYSICIANS REALTY TRUST
DOC
$4.77M 0.18%
265,336
-265,336
-50% -$4.76M
NTRA icon
96
Natera
NTRA
$38.6B
$4.37M 0.17%
485,758
– –
ARDX icon
97
Ardelyx
ARDX
$1.25B
$4.22M 0.16%
639,370
– –
BHC icon
98
Bausch Health
BHC
$2.25B
$3.99M 0.15%
192,000
-233,000
-55% -$3.7M
AMRN
99
Amarin Corp
AMRN
$298M
$3.83M 0.15%
47,815
– –
INVA icon
100
Innoviva
INVA
$1.57B
$3.53M 0.14%
248,803
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.